Electroacupuncture Improves Cardiac Function in Mice with Myocardial Infarction through Glu Neurons in Ventrolateral Periaqueductal Gray.

Researchers have discovered how electroacupuncture may help protect the heart after a heart attack by working through specific brain pathways. In this animal study, scientists used electroacupuncture at the Heart 7 (Shen men) acupuncture point on mice that had experienced myocardial infarction, a type of heart attack caused by blocked blood flow to the heart muscle. The research team found that electroacupuncture significantly improved heart function in these mice. Using advanced neuroscience techniques, they identified that the treatment works by activating specific glutamatergic neurons in a brain region called the ventrolateral periaqueductal gray (vlPAG). When researchers artificially blocked these neurons, electroacupuncture lost its protective effects. Conversely, when they directly activated these same neurons without acupuncture, they saw similar heart-protective benefits. This suggests electroacupuncture creates an "acupoint-brain-heart" communication pathway. The treatment reduced inflammation and helped restore normal heart rhythm and pumping function. While ischemic heart disease remains a leading cause of death worldwide, this study provides scientific evidence for how acupuncture might complement conventional cardiac care. The findings help bridge traditional acupuncture practice with modern neuroscience, showing that needling specific points can trigger beneficial brain responses that protect the heart. Though conducted in mice, this research opens doors for understanding acupuncture's cardiovascular benefits in humans. If you're considering acupuncture for heart-related concerns, consult with both your cardiologist and a licensed acupuncturist trained in Traditional Chinese Medicine.

This study elucidates the central neural mechanism underlying electroacupuncture's cardioprotective effects post-myocardial infarction. Using a murine MI model, researchers demonstrated that EA at HT7 significantly improved cardiac function as measured by echocardiography and histopathology, while reducing inflammatory markers via Western blot and RT-qPCR analysis. Neuronal activity was monitored through c-Fos immunofluorescence and fiber photometry, revealing selective activation of ventrolateral periaqueductal gray (vlPAG) glutamatergic neurons during EA treatment. Chemogenetic manipulation confirmed causality: inhibition of vlPAGGlu neurons abolished EA's cardioprotective effects, while selective activation mimicked EA benefits independent of needling. The study establishes a definitive "acupoint-brain-heart" axis, demonstrating that HT7 stimulation engages specific midbrain circuits to modulate cardiac homeostasis. Clinical implications suggest vlPAG glutamatergic pathways represent novel neuromodulatory targets for integrative cardiovascular therapy. This neurobiological framework supports incorporating EA into post-MI rehabilitation protocols, though human trials are warranted to translate these preclinical findings.